Qingxing Liu
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Deep learning-based non-invasive prediction of PD-L1 status and immunotherapy survival stratification in esophageal cancer using [18F]FDG PET/CT.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 09, 2025
Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 04, 2025
Fully automated 3D multi-modal deep learning model for preoperative T-stage prediction of colorectal cancer using 18F-FDG PET/CT.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 19, 2025
68Ga/177Lu-Labeled Theranostic Pair for Targeting Fibroblast Activation Protein with Improved Tumor Uptake and Retention.
Journal: Journal of medicinal chemistry
Published: September 25, 2024
Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 11, 2024
Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein.
Journal: Bioorganic chemistry
Published: July 04, 2023
Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Journal: Clinical nuclear medicine
Published: April 19, 2023
Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors.
Journal: Theranostics
Published: July 18, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026